title: Pioglitazone induced reversible pancytopenia.
abstract: Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. This group of drugs is usually well tolerated; however, their use may be associated with several adverse effects including edema, weight gain, macular edema and heart failure. Herein we report a patient who developed pancytopenia on the 7th day of oral pioglitazone treatment for the control of diabetes mellitus and fully recovered 6 days after the cessation of this drug. To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy.
authors.affiliation: Endocrinology Department, Fatih University Hospital, 06510 Ankara Turkey.
authors.forename: F
authors.initials: F
authors.lastname: Karakurt
authors.forename: A
authors.initials: A
authors.lastname: Kargili
authors.forename: B
authors.initials: B
authors.lastname: Kasapoglu
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000139:chemically induced*; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone